Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy

Srinivas Iyengar, Garrie Haas, Sumant Lamba, David A. Orsinelli, Gopal Babu, Amy K. Ferketich, Laura Yamokoski, Muthu Periasamy, William T. Abraham

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Cardiac resynchronization therapy (CRT) improves echocardiographic measures of ventricular structure and function in the failing heart. To determine whether or not these changes are representative of true biologic reverse ventricular remodeling or simply an artifact of an improved contraction pattern, we evaluated changes in myocardial gene expression typical of reverse remodeling before and after chronic CRT. Methods and Results: Optimally medically treated patients with nonischemic heart failure meeting standard clinical criteria for CRT were enrolled. Before implantation of a CRT device, baseline echocardiogram and endomyocardial biopsies were obtained. These studies were repeated after 6 months of CRT. Using quantitative reverse-transcriptase polymerase chain reaction, the amount of messenger RNA for selected genes regulating contractile function (sarcoplasmic reticulum Ca2+ ATPase, α- and β-myosin heavy chain [MHC] isoforms, phospholamban [PLB]), and pathologic hypertrophy (β-MHC and atrial natriuretic peptide [ANP]) was determined from biopsy samples. Changes in gene expression (baseline to 6 months) were determined and correlated to changes in echocardiographic remodeling parameters. Ten patients were enrolled in the study, with 7 completing both baseline and follow-up biopsies and echocardiograms. On average, a significant increase was observed in α-MHC and PLB gene expression from baseline to 6 months (P = .016 for both). β-MHC levels tended to decrease with CRT (P = .078). Increased α-MHC levels correlated best with decreases in left ventricular end-diastolic dimension (P = .073, r = -0.71) and reductions in mitral regurgitation. No significant correlation between ejection fraction and gene expression was found. Conclusions: These changes in myocardial gene expression support the occurrence of reverse remodeling during chronic CRT. The changes are similar to those reported previously with β-blockade, but were seen on top of standard drug therapies for heart failure.

Original languageEnglish (US)
Pages (from-to)304-311
Number of pages8
JournalJournal of Cardiac Failure
Volume13
Issue number4
DOIs
StatePublished - May 1 2007
Externally publishedYes

Fingerprint

Cardiac Resynchronization Therapy
Dilated Cardiomyopathy
Myosin Heavy Chains
Gene Expression
Biopsy
Cardiac Resynchronization Therapy Devices
Heart Failure
Ventricular Remodeling
Ventricular Function
Calcium-Transporting ATPases
Mitral Valve Insufficiency
Sarcoplasmic Reticulum
Atrial Natriuretic Factor
Reverse Transcriptase Polymerase Chain Reaction
Artifacts
Hypertrophy
Protein Isoforms
Drug Therapy
Messenger RNA
Genes

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Iyengar, Srinivas ; Haas, Garrie ; Lamba, Sumant ; Orsinelli, David A. ; Babu, Gopal ; Ferketich, Amy K. ; Yamokoski, Laura ; Periasamy, Muthu ; Abraham, William T. / Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy. In: Journal of Cardiac Failure. 2007 ; Vol. 13, No. 4. pp. 304-311.
@article{9917ef3739834e6395f5440a053c9adf,
title = "Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy",
abstract = "Background: Cardiac resynchronization therapy (CRT) improves echocardiographic measures of ventricular structure and function in the failing heart. To determine whether or not these changes are representative of true biologic reverse ventricular remodeling or simply an artifact of an improved contraction pattern, we evaluated changes in myocardial gene expression typical of reverse remodeling before and after chronic CRT. Methods and Results: Optimally medically treated patients with nonischemic heart failure meeting standard clinical criteria for CRT were enrolled. Before implantation of a CRT device, baseline echocardiogram and endomyocardial biopsies were obtained. These studies were repeated after 6 months of CRT. Using quantitative reverse-transcriptase polymerase chain reaction, the amount of messenger RNA for selected genes regulating contractile function (sarcoplasmic reticulum Ca2+ ATPase, α- and β-myosin heavy chain [MHC] isoforms, phospholamban [PLB]), and pathologic hypertrophy (β-MHC and atrial natriuretic peptide [ANP]) was determined from biopsy samples. Changes in gene expression (baseline to 6 months) were determined and correlated to changes in echocardiographic remodeling parameters. Ten patients were enrolled in the study, with 7 completing both baseline and follow-up biopsies and echocardiograms. On average, a significant increase was observed in α-MHC and PLB gene expression from baseline to 6 months (P = .016 for both). β-MHC levels tended to decrease with CRT (P = .078). Increased α-MHC levels correlated best with decreases in left ventricular end-diastolic dimension (P = .073, r = -0.71) and reductions in mitral regurgitation. No significant correlation between ejection fraction and gene expression was found. Conclusions: These changes in myocardial gene expression support the occurrence of reverse remodeling during chronic CRT. The changes are similar to those reported previously with β-blockade, but were seen on top of standard drug therapies for heart failure.",
author = "Srinivas Iyengar and Garrie Haas and Sumant Lamba and Orsinelli, {David A.} and Gopal Babu and Ferketich, {Amy K.} and Laura Yamokoski and Muthu Periasamy and Abraham, {William T.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1016/j.cardfail.2007.01.005",
language = "English (US)",
volume = "13",
pages = "304--311",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "4",

}

Iyengar, S, Haas, G, Lamba, S, Orsinelli, DA, Babu, G, Ferketich, AK, Yamokoski, L, Periasamy, M & Abraham, WT 2007, 'Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy', Journal of Cardiac Failure, vol. 13, no. 4, pp. 304-311. https://doi.org/10.1016/j.cardfail.2007.01.005

Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy. / Iyengar, Srinivas; Haas, Garrie; Lamba, Sumant; Orsinelli, David A.; Babu, Gopal; Ferketich, Amy K.; Yamokoski, Laura; Periasamy, Muthu; Abraham, William T.

In: Journal of Cardiac Failure, Vol. 13, No. 4, 01.05.2007, p. 304-311.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of Cardiac Resynchronization Therapy on Myocardial Gene Expression in Patients with Nonischemic Dilated Cardiomyopathy

AU - Iyengar, Srinivas

AU - Haas, Garrie

AU - Lamba, Sumant

AU - Orsinelli, David A.

AU - Babu, Gopal

AU - Ferketich, Amy K.

AU - Yamokoski, Laura

AU - Periasamy, Muthu

AU - Abraham, William T.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Background: Cardiac resynchronization therapy (CRT) improves echocardiographic measures of ventricular structure and function in the failing heart. To determine whether or not these changes are representative of true biologic reverse ventricular remodeling or simply an artifact of an improved contraction pattern, we evaluated changes in myocardial gene expression typical of reverse remodeling before and after chronic CRT. Methods and Results: Optimally medically treated patients with nonischemic heart failure meeting standard clinical criteria for CRT were enrolled. Before implantation of a CRT device, baseline echocardiogram and endomyocardial biopsies were obtained. These studies were repeated after 6 months of CRT. Using quantitative reverse-transcriptase polymerase chain reaction, the amount of messenger RNA for selected genes regulating contractile function (sarcoplasmic reticulum Ca2+ ATPase, α- and β-myosin heavy chain [MHC] isoforms, phospholamban [PLB]), and pathologic hypertrophy (β-MHC and atrial natriuretic peptide [ANP]) was determined from biopsy samples. Changes in gene expression (baseline to 6 months) were determined and correlated to changes in echocardiographic remodeling parameters. Ten patients were enrolled in the study, with 7 completing both baseline and follow-up biopsies and echocardiograms. On average, a significant increase was observed in α-MHC and PLB gene expression from baseline to 6 months (P = .016 for both). β-MHC levels tended to decrease with CRT (P = .078). Increased α-MHC levels correlated best with decreases in left ventricular end-diastolic dimension (P = .073, r = -0.71) and reductions in mitral regurgitation. No significant correlation between ejection fraction and gene expression was found. Conclusions: These changes in myocardial gene expression support the occurrence of reverse remodeling during chronic CRT. The changes are similar to those reported previously with β-blockade, but were seen on top of standard drug therapies for heart failure.

AB - Background: Cardiac resynchronization therapy (CRT) improves echocardiographic measures of ventricular structure and function in the failing heart. To determine whether or not these changes are representative of true biologic reverse ventricular remodeling or simply an artifact of an improved contraction pattern, we evaluated changes in myocardial gene expression typical of reverse remodeling before and after chronic CRT. Methods and Results: Optimally medically treated patients with nonischemic heart failure meeting standard clinical criteria for CRT were enrolled. Before implantation of a CRT device, baseline echocardiogram and endomyocardial biopsies were obtained. These studies were repeated after 6 months of CRT. Using quantitative reverse-transcriptase polymerase chain reaction, the amount of messenger RNA for selected genes regulating contractile function (sarcoplasmic reticulum Ca2+ ATPase, α- and β-myosin heavy chain [MHC] isoforms, phospholamban [PLB]), and pathologic hypertrophy (β-MHC and atrial natriuretic peptide [ANP]) was determined from biopsy samples. Changes in gene expression (baseline to 6 months) were determined and correlated to changes in echocardiographic remodeling parameters. Ten patients were enrolled in the study, with 7 completing both baseline and follow-up biopsies and echocardiograms. On average, a significant increase was observed in α-MHC and PLB gene expression from baseline to 6 months (P = .016 for both). β-MHC levels tended to decrease with CRT (P = .078). Increased α-MHC levels correlated best with decreases in left ventricular end-diastolic dimension (P = .073, r = -0.71) and reductions in mitral regurgitation. No significant correlation between ejection fraction and gene expression was found. Conclusions: These changes in myocardial gene expression support the occurrence of reverse remodeling during chronic CRT. The changes are similar to those reported previously with β-blockade, but were seen on top of standard drug therapies for heart failure.

UR - http://www.scopus.com/inward/record.url?scp=34248595516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248595516&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2007.01.005

DO - 10.1016/j.cardfail.2007.01.005

M3 - Article

VL - 13

SP - 304

EP - 311

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 4

ER -